TLX shares rise about 5% ahead of FDA decision next Friday
NASDAQ-listed Telix Pharmaceuticals (TLX) climbed for the week as investors focused on a U.S. FDA decision due next Friday on its brain-cancer imaging agent. TLX traded around $11.90 on Friday.
NASDAQ-listed shares of Telix Pharmaceuticals (TLX) rose this week as investors waited for a U.S. Food and Drug Administration decision next Friday on the company’s brain-cancer imaging agent. TLX stock was trading around $11.90 on Friday, up roughly 5% from last Friday’s close of $11.2.